In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Scots say yes to cancer drugs after patients have their say

This article was originally published in Scrip

Executive Summary

Using a new process that involves greater patient input, Scotland's health technology appraisal body, the Scottish Medicines Consortium, has okayed for use on the local NHS three anticancers that England has so far largely rejected for use on its NHS. Ariad's Iclusig (ponatinib), Boehringer Ingelheim's Vargatef (nintedanib) and Bayer's Stivarga (regorafenib) have all been given the green light in Scotland.



Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts